

**SUMMARY:** The Food and Drug Administration (FDA) is requesting nominations for voting members to serve on the Tobacco Products Scientific Advisory Committee, Office of Science, Center for Tobacco Products.

FDA seeks to include the views of women and men, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore, encourages nominations of appropriately qualified candidates from these groups.

**DATES:** Nominations received on or before December 8, 2014 will be given first consideration for membership on the Tobacco Products Scientific Advisory Committee. Nominations received after December 8, 2014 will be considered for nomination to the committee as later vacancies occur.

**ADDRESSES:** All nominations for membership should be submitted electronically by logging into the FDA Advisory Committee Membership Nomination Portal: <https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm>, by mail to Advisory Committee Oversight and Management Staff, Food and Drug Administration 10903 New Hampshire Ave., Bldg. 32, rm. 5103, Silver Spring, MD 20993-0002, or by FAX to 301-847-8640.

Information about becoming a member on an FDA advisory committee can also be obtained by visiting FDA's Web site at: <http://www.fda.gov/AdvisoryCommittees/default.htm>.

**FOR FURTHER INFORMATION CONTACT:** *Regarding all nomination questions for membership, the primary contact is:* Caryn Cohen, Office of Science, Center for Tobacco Products, Center for Tobacco Products Document Control Center, Food and Drug Administration, 10903 New Hampshire Avenue, Bldg. 71, rm. G335, Silver Spring, MD 20993-0002, 1-877-287-1373 (choose Option 5), FAX: 240-276-3655, email: [TPSAC@fda.hhs.gov](mailto:TPSAC@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** FDA is requesting nominations for voting members on the Tobacco Products Scientific Advisory Committee.

### **I. General Description of the Committee Duties**

The Tobacco Products Scientific Advisory Committee (the Committee) advises the Commissioner of Food and Drugs (the Commissioner) or designee in discharging responsibilities related to the regulation of tobacco products. The Committee reviews and evaluates safety, dependence, and health issues relating to tobacco products and provides

appropriate advice, information, and recommendations to the Commissioner.

### **II. Criteria for Voting Members**

The Committee consists of 12 members including the Chair. Members and the Chair are selected by the Commissioner or designee from among individuals knowledgeable in the fields of medicine, medical ethics, science, or technology involving the manufacture, evaluation, or use of tobacco products. Members are invited to serve for overlapping terms of up to 4 years. Almost all non-Federal members of this committee serve as Special Government Employees. The Committee includes nine technically qualified voting members, selected by the Commissioner or designee. The nine voting members include seven members who are physicians, dentists, scientists, or health care professionals practicing in the area of oncology, pulmonology, cardiology, toxicology, pharmacology, addiction, or any other relevant specialty. The nine voting members also include one member who is an officer or employee of a state or local government or of the Federal Government, and one member who is a representative of the general public.

In addition to the voting members, the Committee includes three nonvoting members who are identified with industry interests. These members include one representative of the interests of the tobacco manufacturing industry, one representative of the interests of tobacco growers, and one representative of the interests of the small business tobacco manufacturing industry, which position may be filled on a rotating, sequential basis by representatives of different small business tobacco manufacturers based on areas of expertise relevant to the topics being considered by the Committee.

### **III. Nomination Procedures**

Any interested person may nominate one or more qualified individuals for membership on the Committee. Self-nominations are also accepted. Nominations must include a current, complete résumé or curriculum vitae for each nominee, including current business address and/or home address, telephone number, and email address if available. Nominations must also specify the advisory committee for which the nominee is recommended. Nominations must also acknowledge that the nominee is aware of the nomination unless self-nominated. FDA will ask potential candidates to provide detailed information concerning such matters as financial holdings,

employment, and research grants and/or contracts to permit evaluation of possible sources of conflicts of interest.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

Dated: October 3, 2014.

**Jill Hartzler Warner,**

*Associate Commissioner for Special Medical Programs.*

[FR Doc. 2014-24074 Filed 10-8-14; 8:45 am]

**BILLING CODE 4164-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **Indian Health Service**

#### **Policy on Conferring With Urban Indian Organizations; Correction**

**AGENCY:** Indian Health Service, HHS.

**ACTION:** Notice; correction.

**SUMMARY:** The Indian Health Service is issuing this Notice to correct the effective date from October 29, 2014 to September 22, 2014 for the final Policy for Conferring with Urban Indian Organizations. The notice published at 79 FR 58359, September 29, 2014.

**FOR FURTHER INFORMATION CONTACT:** Office of Management Services, Management Policy and Internal Control Staff, Indian Health Service, 801 Thompson Avenue, Suite 625A, Rockville, MD 20852, Telephone (301) 443-2650. (This is not a toll-free number.)

#### **Correction**

In the **Federal Register** of September 29, 2014, in FR Doc. 2014-23005, on page 58359, in the third column, following **DATES** the correct date should read as follows:

This Policy is effective September 22, 2014.

Dated: October 3, 2014.

**Yvette Roubideaux,**

*Acting Director, Indian Health Service.*

[FR Doc. 2014-24154 Filed 10-8-14; 8:45 am]

**BILLING CODE 4165-16-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as